A revenue-generating, small-cap Canadian pharmaceutical company
Revenue Projected at $150,000,000 by 2025
Message: INTERVIEW ALERT: Valeo Pharma (VPH: CSE) (VPHIF: OTCQB)
We just sat down with Valeo Pharma CEO Steve Saviuk.
We discuss:
- First provincial public listing for both asthma medications
- Additional provincial public reimbursement coverage expected soon
- 85% private payer health plan coverage across Canada
- All this less than 5 months after commercial launch
OUT TONIGHT
New Message
Please
login
to post a reply